Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T00:38:21.429Z Has data issue: false hasContentIssue false
  • English
  • Français

Cariprazine in Negative Symptoms of Schizophrenia: Post-hoc Analyses of a Fixed-dose Phase Iii, Randomized, Double-blind, Placebo- and Active-controlled Trial

Published online by Cambridge University Press:  15 April 2020

M. Debelle ,
S. Faradzs-zade ,
B. Szatmari ,
K. Nagy ,
G. Nemeth ,
S. Durgam  and
I. Laszlovszky
M. Debelle
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary
S. Faradzs-zade
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary
B. Szatmari
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary
K. Nagy
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary
G. Nemeth
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary
S. Durgam
Affiliation:
Medical Department, Forest Research Institute, Jersey city, USA
I. Laszlovszky
Affiliation:
Medical Department, Gedeon Richter, Budapest, Hungary

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Cariprazine, a dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors, is being developed for the treatment of schizophrenia

Objective

To explore the effect of cariprazine on negative symptoms of schizophrenia.

Methods

Subjects aged 18-60 years with acute schizophrenia, current acute episode >2 weeks, and a PANSS total score ≥80 and ≤120 were randomly allocated in a 6-Week study NCT01104766 to cariprazine 3 mg/d, cariprazine 6 mg/d, aripiprazole 10 mg/d (active control), or placebo [1]. Post–hoc analyses were performed on subjects with severe negative symptoms and low-to-moderate positive symptoms, defined according to Marder.

Results of the Post-Hoc Analyses

Data of 26 subjects were included in the cariprazine 3 mg/d (17.2% of the total sample), 34 in the cariprazine 6 mg/d (22.1%), 35 in the aripiprazole (23.3%) and 35 in the placebo (23.5%) groups, respectively. Change from baseline to Week 6 in the PANSS Factor Score for Negative Symptoms (PFSNS) was statistically significant for cariprazine 6 mg/d versus placebo (least squares mean difference: cariprazine 3 mg/d=-2.15, p= 0.20; cariprazine 6 mg/d = −3.68, p=.019). Cariprazine 6 mg/d was superior to placebo at each weekly assessment from Week 3. The changes in PFSNS for aripiprazole were not statistically significant at any weekly assessment.

Conclusion

Post–hoc analyses performed on subjects with acute schizophrenia, high level of negative symptoms and low-to-moderate positive symptoms, showed that the patients in the cariprazine 6 mg/d group had a significantly greater improvement relative to placebo on the PFSNS.

Type
Article: 0242
Information
European Psychiatry , Volume 30 , Issue S1: Abstracts of the 23rd European Congress of Psychiatry , March 2015 , pp. 1
Copyright
Copyright © European Psychiatric Association 2015

References

Lieberman, JAEur Neuropsychopharm 23 (Suppl2) 2013 S477–S44810.1016/S0924-977X(13)70756-9CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.